Theranos Model: (Direct competition)
Personal niche/expertise in oncogenic signalling pathways.
Recognition of cancer-relevant perturbances beyond direct mutational burden
Objective: Early identification of oncogenesis prior to tumorigenesis
Early personalized diagnostics
Focus: molecular markers for oncological diagnosis:
I. Genomic Markers
Extract Biomaterial
extract sequence -
determine mutational burden
Calculate iso factor for disease type
Novelty:
Use latest TCAG and basic research data
Streamline using family history - direct extraction from electronic repositories
II. Proteomic Markers
Extract Biomaterial
extract ? - mass spec - others?
determine 'aberrant proteome' burden
- Misexpression - folding
- PTMs indicative of perturbed function
- post-translational variables that establish dominant negatives
- must streamline early to focus on indispensible factors/pathways - pRB, p53 etc. as 'last checkpoint barriers'
- Calculate iso factor for disease type
Novelty:
Use latest proteomic and basic research data
Streamline using family history - direct extraction from electronic repositories
III. Patient-directed use
Design easy system for biomaterial extraction
Design easy system for material processing
cloud updates for up-to-date lit-based consolidation
easy output on phones
MD accessibility
Personal niche/expertise in oncogenic signalling pathways.
Recognition of cancer-relevant perturbances beyond direct mutational burden
Objective: Early identification of oncogenesis prior to tumorigenesis
Early personalized diagnostics
Focus: molecular markers for oncological diagnosis:
I. Genomic Markers
Extract Biomaterial
extract sequence -
determine mutational burden
Calculate iso factor for disease type
Novelty:
Use latest TCAG and basic research data
Streamline using family history - direct extraction from electronic repositories
II. Proteomic Markers
Extract Biomaterial
extract ? - mass spec - others?
determine 'aberrant proteome' burden
- Misexpression - folding
- PTMs indicative of perturbed function
- post-translational variables that establish dominant negatives
- must streamline early to focus on indispensible factors/pathways - pRB, p53 etc. as 'last checkpoint barriers'
- Calculate iso factor for disease type
Novelty:
Use latest proteomic and basic research data
Streamline using family history - direct extraction from electronic repositories
III. Patient-directed use
Design easy system for biomaterial extraction
Design easy system for material processing
cloud updates for up-to-date lit-based consolidation
easy output on phones
MD accessibility